Erleada is a cancer medicine used to treat men with cancer of the prostate (a gland of the male reproductive system). It is used when the cancer is not responding to treatments that lower testosterone levels (castration resistant) and is at high risk of spreading to other parts of the body. It is also used when the cancer has spread to other parts of the body (metastatic) but responds to treatment that lowers testosterone levels (hormone sensitive). Erleada is used in combination with a treatment called androgen deprivation therapy. Erleada contains the active substance apalutamide.
Therapeutic Indication
### Therapeutic indication Erleada is indicated: - in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. - in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Therapeutic Area (MeSH)
ATC Code
L02BB05
ATC Item
apalutamide
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| apalutamide | N/A | 阿帕他胺 |
EMA Name
Erleada
Medicine Name
Erleada
Aliases
N/ANo risk management plan link.
